May 18, 2017
May 18, 2017 —
Antiva Biosciences, a spinout of UC San Diego, closed a $22M Series C financing in March. Antiva is a clinical stage biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by Human Papilloma Virus (HPV) infection. Osage University Partners, a venture capital firm partnered with UC San Diego that invests exclusively in startups that are commercializing university research, invested in this round.
May 11, 2017
May 11, 2017 —
Researchers at University of California San Diego School of Medicine, with collaborators across the nation, have determined that magnetic resonance elastography (MRE) can be an accurate, non-invasive tool to identify liver fibrosis in children. Nonalcoholic fatty liver disease (NAFLD) is now the most common cause of chronic liver disease in children, and scarring of the liver, known as fibrosis, is a major determinant of clinical outcomes.
May 11, 2017
May 11, 2017 —
A sampling of the works from artist Ted Meyer’s intriguing Scarred for Life series will be on display, beginning May 15 through September 1, 2017, in the Biomedical Library Building breezeway. The exhibit and an opening reception on May 15 are a collaboration between the UC San Diego Library and Oceanside Museum of Art, which is holding a major exhibition of the artist’s work—Ted Meyer: Scarred for Life— from May 27 through September 17, 2017.
May 10, 2017
May 10, 2017 —
Researchers at the University of California San Diego School of Medicine, with colleagues in Ecuador and Minnesota, have found altered short-term neurological behaviors in children associated with a peak pesticide spraying season linked to the Mother’s Day flower harvest. This study examined children who did not work in agriculture but who lived in agricultural communities in Ecuador.
May 3, 2017
May 3, 2017 —
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego mined the FDA Adverse Effect Reporting System (FAERS) database for depression symptoms in patients taking ketamine for pain. They found that depression was reported half as often among the more than 41,000 patients who took ketamine, as compared to patients who took any other drug or drug combination for pain.
May 2, 2017
May 2, 2017 —
The U.S. National Academy of Sciences announced today the membership election of Christopher K. Glass, MD, PhD, professor in the Departments of Medicine and Cellular and Molecular Medicine at University of California San Diego School of Medicine.
May 2, 2017
May 2, 2017 —
Pancreatic beta cells help maintain normal blood glucose levels by producing the hormone insulin — the master regulator of energy (glucose). Impairment and the loss of beta cells interrupts insulin production, leading to type 1 and 2 diabetes. Using single-cell RNA sequencing, researchers at University of California San Diego School of Medicine have, for the first time, mapped out pathways that regulate beta cell growth that could be exploited to trick them to regenerate.
May 2, 2017
May 2, 2017 —
Nonalcoholic fatty liver disease (NAFLD) — a condition that can lead to liver cirrhosis and cancer — isn’t typically detected until well advanced. Even then, diagnosis requires a biopsy. To more easily detect NAFLD, UC San Diego School of Medicine researchers and their collaborators report that the microbial makeup of a patient’s stool — gut microbiome — can be used to predict advanced NAFLD with 88 to 94 percent accuracy. The study is published May 2 in Cell Metabolism.
May 1, 2017
May 1, 2017 —
The next installment of the UC San Diego series, Evening with an Entrepreneur, will feature scientist, inventor, serial entrepreneur, innovator, and long-time UC San Diego supporter, Dr. Tina Nova. Nova will sit down with Biocom’s Joe Panetta for an interview to discuss her unique entrepreneurial background and success in molecular diagnostics.
April 26, 2017
April 26, 2017 —
UC San Diego announced its first eight proof-of-concept awards to advance university inventions to commercial impact. Funded through the new “Accelerating Innovations to Market (AIM)” program, these milestone-driven projects are designed to de-risk early-stage technologies.
